Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol.15, 10–17 (1983).
   PubMed Web of Science ®Google Scholar
• Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr. Opin. Obstet. Gynecol.22(1), 21–29 (2010).
   PubMed Web of Science ®Google Scholar
• Rose PG. Endometrial carcinoma. N. Engl. J. Med.335(9), 640–649 (1996).
   PubMed Web of Science ®Google Scholar
• Schwartz PE. The management of serous papillary uterine cancer. Curr. Opin. Oncol.18(5), 494–499 (2006).
   PubMed Web of Science ®Google Scholar
• Goff BA. Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol. Oncol.98(3), 341–343 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Cheung MK, Osann K et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer94(5), 642–646 (2006).
   PubMed Web of Science ®Google Scholar
• Maxwell GL, Tian C, Risinger J et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a gynecologic oncology group study. Cancer107(9), 2197–2205 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer98(1), 176–186 (2003).
   PubMedGoogle Scholar
• Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A. Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch. Gyneco. Obstet.271(1), 62–65 (2005).
   PubMedGoogle Scholar
• Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur. J. Surg. Oncol.32(10), 1097–1100 (2006).
   PubMed Web of Science ®Google Scholar
• Kelly MG, O’Malley DM, Hui P et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol.98(3), 353–359 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda SM, Kapp DS, Cheung MK et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am. J. Obstet. Gynecol.198(2), 218.e1–218.e6 (2008).
   Web of Science ®Google Scholar
• Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. [Erratum in Lancet Oncol.7(2), 105 (2006)]. Lancet Oncol.6(12), 961–971 (2005).
   Google Scholar
• Hamilton CA, Liou WS, Osann K et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys.63(3), 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Martin JD, Gilks B, Lim P. Papillary serous carcinoma – a less radio-sensitive subtype of endometrial cancer. Gynecol. Oncol.98(2), 299–303 (2005).
   PubMedGoogle Scholar
• Alektiar KM, Makker V, Abu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer. Gynecol. Oncol.112(1), 142–145 (2009).
   PubMedGoogle Scholar
• Santin AD, Bellone S, Van Stedum S et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer104(7), 1391–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol.16(6), 600–610 (1992).
   PubMed Web of Science ®Google Scholar
• Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int. J. Gynecol. Pathol.23(2), 119–122 (2004).
   PubMedGoogle Scholar
• Moreno-Bueno G, Sanchez-Estevez C, Cassia R et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res.63(18), 5697–5702 (2003).
   PubMed Web of Science ®Google Scholar
• Risinger JI, Maxwell GL, Chandramouli GV et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res.63(1), 6–11 (2003).
   PubMed Web of Science ®Google Scholar
• Santin AD, Zhan F, Cane’ S et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br. J. Cancer92(8), 1561–1573 (2005).
   PubMed Web of Science ®Google Scholar
• Santin AD, Zhan F, Bellone S et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br. J. Cancer90(9), 1814–1824 (2004).
   PubMedGoogle Scholar
• Ragni N, Ferrero S, Prefumo F et al. The association between p53 expression, stage and histological features in endometrial cancer. Eur. J. Obstet. Gynecol. Reprod. Biol.123(1), 111–116 (2005).
   PubMedGoogle Scholar
• Jongen VH, Briet JM, de Jong RA et al. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int. J. Gynecol. Cancer19(4), 670–676 (2009).
   PubMedGoogle Scholar
• Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Archiv.444(3), 213–223 (2004).
   PubMed Web of Science ®Google Scholar
• Shedden KA, Kshirsagar MP, Schwartz DR et al. Histologic type, organ of origin, and wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin. Cancer Res.11(6), 2123–2131 (2005).
   PubMedGoogle Scholar
• Cocco E, Bellone S, El-Sahwi K et al. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Cancer101(2), 335–341 (2009).
   PubMedGoogle Scholar
• Yarden Y, Sliwkowski MX. Untangling the erbB signalling network. Nature Rev. Mol. Cell Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res.50(13), 4087–4091 (1990).
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rodriguez G, Kinney RB et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol.164(1 Pt 1), 15–21 (1991).
   PubMed Web of Science ®Google Scholar
• Hetzel DJ, Wilson TO, Keeney GL, HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol.47(2), 179–185 (1992).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Gokden M et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin. Cancer Res8(5), 1271–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Siegel ER et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol.192(3), 813–818 (2005).
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E et al.In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br. J. Cancer102(1), 134–143 (2010).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Van Stedum S et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol. Oncol.98(1), 24–30 (2005).
   PubMed Web of Science ®Google Scholar
• Diaz-Montes TP, Ji H, Smith Sehdev AE et al. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol. Oncol.100(1), 139–144 (2006).
   PubMed Web of Science ®Google Scholar
• Grushko TA, Filiaci VL, Mundt AJ et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol. Oncol.108(1), 3–9 (2008).
   PubMed Web of Science ®Google Scholar
• Odicino FE, Bignotti E, Rossi E et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int. J. Gynecol. Cancer18(1), 14–21 (2008).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer94(2), 259–267 (2006).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6(4), 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res.10(17), 5650–5655 (2004).
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated erbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell2(2), 127–137 (2002).
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol.23(11), 2534–2543 (2005).
   PubMed Web of Science ®Google Scholar
• Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol. Cancer Ther.6(1), 93–100 (2007).
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res.64(7), 2343–2346 (2004).
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res.69(24), 9330–9336 (2009).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.116(1), 15–20 (2010).
   PubMed Web of Science ®Google Scholar
• Santin AD. Letter to the editor referring to the manuscript entitled: ‘Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a gynecologic oncology group study’ recently reported by Fleming et al. (Gynecol. Oncol.,116, 15–20 (15)). Gynecol. Oncol.118(1), 95–96 (2010).
   Google Scholar
• Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet.102(2), 128–131 (2008).
   PubMed Web of Science ®Google Scholar
• Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer16(5), 1897–1902 (2006).
   PubMed Web of Science ®Google Scholar
• Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int. J. Gynecol. Cancer16(3), 1370–1373 (2006).
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. CLEOPATRA: a Phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin. Breast Cancer10(6), 489–491 (2010).
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E et al. Overexpression of EpCAM in uterine serous papillary carcinoma: Implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol. Cancer Ther.9(1), 57–66 (2010).
   PubMed Web of Science ®Google Scholar
• Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J. Biol. Chem.272(42), 26652–26658 (1997).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Marizzoni M et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer109(7), 1312–1322 (2007).
   PubMedGoogle Scholar
• Diamandis EP, Scorilas A, Fracchioli S et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol.21(6), 1035–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Santin AD, Diamandis EP, Bellone S et al. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin. Cancer Res.11(9), 3320–3325 (2005).
   PubMedGoogle Scholar
• Santin AD, Diamandis EP, Bellone S et al. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am. J. Obstet. Gynecol.194(5), 1296–1302 (2006).
   PubMedGoogle Scholar
• Paik D, Cocco E, Bellone S et al. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol. Oncol.119(1), 140–145 (2010).
   PubMedGoogle Scholar
• Cross SN, Cocco E, Bellone S et al. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am. J. Obstet. Gynecol.203(2), 162.e1–8 (2010).
   Google Scholar
• Cocco E, Hu Z, Richter CE et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br. J. Cancer103(6), 812–819 (2010).
   PubMedGoogle Scholar
• Bellone S, Watts K, Cane’ S et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol. Oncol.98(1), 92–98 (2005).
   PubMedGoogle Scholar
• Bellone M, Cocco E, Varughese J et al. Expression of alphaV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-alphaV-integrin antibody. Int. J. Gynecol. Cancer21(6), 1084–1090 (2011).
   PubMedGoogle Scholar
• Todeschini P, Cocco E, Bellone S et al. Her2/neu extracellular domain shedding in uterine serous carcinoma; implications for immunotherapy with trastuzumab. Br. J. Cancer105(8), 1176–1182 (2011).
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S et al. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Cancer117(14), 3163–3172 (2011).
   PubMed Web of Science ®Google Scholar